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Prion diseases are associated with the presence of PrPSc, a disease-associated misfolded conformer of the
prion protein. We report that superparamagnetic nanoparticles bind PrPSc molecules efficiently and specifically, permitting magnetic separation of prions from a sample mixture. Captured PrPSc molecules retain the
activity to seed protein misfolding cyclic amplification (PMCA) reactions, enabling the rapid concentration of
dilute prions to improve detection. Furthermore, superparamagnetic nanoparticles clear contaminated solutions of PrPSc. Our findings suggest that coupling magnetic nanoparticle capture with PMCA could accelerate
and improve prion detection. Magnetic nanoparticles may also be useful for developing a nontoxic prion
decontamination method for biologically derived products.
PrPSc may be applied to prion detection and prion decontamination.

Bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, and other prion diseases are caused by an infectious
agent that contains PrPSc, a misfolded conformer of the normal
cellular prion protein (PrPC) (24). Low-abundance sources of
prions, such as blood, may still transmit disease (17, 23). Prion
diseases currently have no therapy, nor can prions be specifically removed from contaminated material.
Inoculation bioassay serves as the gold standard for specific
detection of prion infectivity. For sensitive detection, protein
misfolding cyclic amplification (PMCA) has emerged as a
rapid alternative to bioassay. PMCA exploits prion multiplication mechanisms to amplify PrPSc in vitro using PrPC substrate
(1, 5). Analogous to amplification of DNA sequence template
by PCR, PrPSc template seeds the conversion of PrPC substrate
in PMCA, resulting in propagation and amplification of the PrPSc
conformation. Each serial PMCA round increases the detection
sensitivity exponentially but requires ⬃72 h (7). The application
of PMCA is also limited by prion propagation inhibitors present
in blood and other biological solutions (6). An effective method to
concentrate prions would improve subsequent PMCA sensitivity
and utility.
Nanotechnology presents many opportunities for fine control of molecular events. Certain iron oxide crystals less than
⬃25 nm in diameter exhibit superparamagnetism, with a net
magnetization only occurring in the presence of an external
magnetic field (15). MagnaBind and Dynal superparamagnetic
beads contain many iron oxide crystals, dispersed such that no
permanent magnetic order can form. This enables the whole
particles to be superparamagnetic, allowing them to be rapidly
attracted to a magnet and to lose magnetic interactions upon
removal of the magnet (28). In molecular biology, superparamagnetic beads are often conjugated to specifically bind a
target molecule.
Using superparamagnetic nanoparticles, we have identified
a novel binding interaction with PrPSc. Magnetic capture of

MATERIALS AND METHODS
Preparation of scrapie-infected and uninfected brain homogenate. CD-1
mouse (prion strains RML, Me7, and 301C) and Syrian hamster (prion strains
Sc237 and 139H) scrapie-infected brains were homogenized (Covidien tissue
grinder; Covidien, Mansfield, MA) to 10% in phosphate-buffered saline (PBS),
pH 7.4 (Cellgro, Manassas, VA). Uninfected CD-1 mouse and Syrian hamster
brains (Biochemed, Winchester, VA) were homogenized in the same manner.
The homogenates were initially clarified by centrifugation at 200 ⫻ g for 30 s and
stored at ⫺70°C. Freshly clarified 5% homogenate for each experiment was
prepared by adding an equal volume of Tris-buffered saline (TBS; 50 mM Tris,
200 mM NaCl, pH 7.5), vortexing for 15 s, sonicating (Misonix 4000 with microplate horn; Qsonica, Newtown, CT) for 1 min, and centrifuging at 500 ⫻ g for
15 min.
Preparation of magnetic particles. The superparamagnetic beads used in these
studies were MagnaBind (Pierce, Rockford, IL) or Dynal (Invitrogen, Carlsbad,
CA) bearing either protein A or streptavidin conjugates. All magnetic particles
were separated from solution with a magnetic particle separator (PureBiotech,
Middlesex, NJ).
Nonbead nanoparticles were prepared as follows: 10-nm iron(II,III) oxide (Fe3O4,
magnetite) nanoparticles (Sigma, St. Louis, MO) in toluene were mixed with an
equal volume of methanol and magnetically separated. ⬍50-nm iron(II,III) oxide
(Fe3O4, magnetite) nanopowder was also obtained from Sigma. For silanization
(21), nanoparticles or nanopowder was resuspended in methanol to 0.11 mg/ml, to
which was added 1/10 volume 3-(trimethoxy-silyl)propyl methacrylate (Sigma). Each
was sonicated for 1 min at 70% power and then incubated for 4.5 h at 25°C with 300
rpm shaking. Each was then rinsed in methanol and then ethanol.
Binding assays. Unless otherwise noted, 25 l of beads (5 mg/ml) or 2 mg of
magnetite (10-nm nanoparticles or ⬍50-nm nanopowder, as described above)
was rinsed twice in 500 l PBS plus 0.5% Triton X-100 and then incubated in 150
l of assay buffer (TBS, 1% Triton X-100, 1% Tween 20) with 5 l of clarified
5% brain homogenate overnight at room temperature with 10-rpm end-over-end
rotation. IgG 89-112 anti-PrPSc antibody (18) was added to designated samples
at 7.5 g/ml. Particles were separated from the solution and rinsed twice in 500
l of wash buffer (TBS, 0.05% Tween 20) before analysis of bound molecules.
PrPSc/PrPC comparison reactions were carried out in TBS with 3% NP-40 and
3% Tween 20 for 2 h, followed by four 1-ml washes in TBS with 2% sarkosyl.
PMCA. Following binding, samples were resuspended in 10% CD-1 mouse or
Syrian hamster brain homogenate, which was prepared in conversion buffer
(PBS, 1% Triton X-100, Roche Complete mini protease inhibitor) (6) with an
additional 4 mM EDTA. One round of PMCA consisted of 30 s of microplate
horn sonication pulses every 30 min for 24 h at 90% power.
Prion protein detection. Bound PrPSc was detected by subjecting beads to
limited proteolysis in 50 l (25 g/ml for mouse, 50 g/ml for hamster) of
proteinase K (Roche, Indianapolis, IN) in PBS, 1% Triton X-100. Proteolysis
proceeded for 30 min (mouse) or 60 min (hamster) at 37°C and 750-rpm shaking
and was terminated by the addition of 17 l of 4⫻ sample buffer (217 mM Tris,
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FIG. 1. Binding of PrPSc to MagnaBind superparamagnetic beads.
Bound PrPSc was detected by proteinase K digestion and anti-PrP
(6D11) immunoblot. (A) RML scrapie-infected mouse brain homogenate was incubated with MagnaBind (Mag) or Dynal (Dyn) magnetic
beads linked to protein A or streptavidin. One set of magnetic beadprotein A reaction mixtures was coincubated with IgG 89-112, which
recognizes PrPSc. (B) Binding of PrPSc to MagnaBind-protein A beads
treated for protein disruption. MagnaBind-protein A beads were pretreated by proteinase K digestion (25 g/ml), boiling (95°C for 10 min),
or centrifugation (14,000 ⫻ g for 10 min). Untreated MagnaBindprotein A and control Dynal-protein A beads were also tested. Following these treatments, beads were washed and incubated overnight
with RML scrapie-infected mouse brain homogenate.

pH 6.8, 8.7% [wt/vol] sodium dodecyl sulfate, 21% [vol/vol] glycerol, 0.02%
[wt/vol] bromophenol blue, 3 M ␤-mercaptoethanol) and 10 min of incubation at
95°C. PrP was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), semidry transfer to polyvinylidene difluoride (PVDF)
membrane, immunoblot with anti-PrP antibody 6D11, horseradish peroxidase
(HRP)-conjugated anti-mouse sheep antibody, and enhanced chemiluminescence (SuperSignal West Femto Substrate; Pierce, Rockford, IL). Signals were
visualized by a Fuji (Fujifilm) LAS-3000 chemiluminescence documentation
system.
Silver stain detection of total protein. Following SDS-PAGE, the gel was fixed
overnight in 50% ethanol–10% acetic acid and then treated with two 10-min
washes in 10% ethanol to remove SDS. Next, the gel was incubated for 2 min in
Farmer’s solution (0.3 g sodium thiosulfate, 0.15 g potassium ferricyanide, 0.05 g
sodium carbonate in 100 ml water), followed by four 20-min washes in water and
then 12 min of silver staining (0.2 g silver nitrate in 100 ml water). The gel was
then treated with developer (3 g sodium carbonate, 50 l fresh 37% formaldehyde, 100 ml water) for a short rinse and subsequently incubated for approximately 8 min. The progression of the staining was halted by the addition of stop
solution (5% acetic acid in water).

RESULTS
In the course of performing immunoprecipitation reactions, we observed that protein A- and streptavidin-conjugated MagnaBind magnetic particles bound PrPSc (Fig. 1A).
The binding did not depend on the presence of anti-PrP
antibodies, as antibody-free control reaction mixtures also
precipitated PrPSc (Fig. 1A, lane 2). The interaction was not
due to the protein A moiety conjugated to the particles, as
protein A-Dynabeads did not bind PrPSc without the addition of an anti-PrP antibody (Fig. 1A, lane 3). Furthermore,
MagnaBind beads conjugated to streptavidin also bound
PrPSc, while streptavidin-conjugated Dynabeads did not
(Fig. 1A, lanes 6 and 7). We performed various protein
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FIG. 2. Binding of PrPSc to MagnaBind, silanized nanomagnetite,
and unsilanized nanomagnetite. RML scrapie-infected mouse brain
homogenate was incubated with various quantities of MagnaBind protein A beads (0.005 to 0.125 mg), silanized magnetite nanoparticles (10
nm in size, 0.005 to 2 mg), silanized magnetite nanopowder (⬍50 nm
in size, 0.005 to 2 mg), unsilanized magnetic nanoparticles (0.0015 to 2
mg), or unsilanized magnetic nanopowder (0.0015 to 2 mg). PrPSc
molecules were detected by proteinase K digestion and anti-PrP
(6D11) immunoblot.

disruption treatments to further test whether protein A
played any role in MagnaBind-protein A interaction with
PrPSc. Neither protease treatment nor boiling abrogated
MagnaBind’s ability to bind PrPSc molecules (Fig. 1B), further suggesting that MagnaBind beads alone bind PrPSc.
MagnaBind beads are composed of silanized superparamagnetic iron oxide. Dynabeads also contain superparamagnetic
iron oxide but are completely enveloped by a polystyrene coat
of uniform thickness, which presumably prevents interaction
with PrPSc. Superparamagnetism is exhibited only by small
nanoparticles. To further dissect the MagnaBind-PrPSc interaction and to identify simple reagents for prion capture, we
tested defined particles with a composition similar to the
MagnaBind silane-coated iron oxide. Silanized magnetite
(Fe3O4) nanoparticles captured PrPSc in a dose-dependent
manner (Fig. 2). Interestingly, magnetite nanoparticles alone
(nonsilanized) also captured PrPSc, with 10-nm nanoparticles
and ⬍50-nm nanopowder performing similarly. This suggests
that the prion-capturing activity of MagnaBind beads can be
recapitulated by magnetite nanoparticles. Moreover, PrPSc appears to interact directly with the Fe3O4 metal surface.
Distinct strains of prions infect different brain regions and
display various biochemical properties, despite possessing
identical PrP amino acid sequences (4). We assessed whether
multiple prion strains can be magnetically captured and found
that MagnaBind beads bound all strains examined, including
mouse strains RML, 301C, and Me7 and hamster 139H (Fig.
3). This result suggests that magnetic nanoparticles could be
used as a general prion capture reagent, including for strain
301C, which are mouse-adapted bovine spongiform encephalopathy (BSE) prions (3). Magnetic particle capture of prions
appears to target a general feature of PrPSc that is conserved
between strains and shared among prions from different animal species, which bear different prion protein sequences.
We next examined the selectivity of magnetic capture for

VOL. 85, 2011

SUPERPARAMAGNETIC NANOPARTICLE CAPTURE OF PRIONS

FIG. 3. Binding of diverse strains of PrPSc molecules to MagnaBind
or Dynal beads. Brain homogenates from animals infected with various
prion strains (mouse 301C, mouse RML, mouse Me7, and hamster
139H) were incubated overnight with MagnaBind-protein A or protein
A-Dynal beads. Input and bound PrPSc molecules were detected by
proteinase K digestion and anti-PrP (6D11) immunoblot.

PrPSc. Magnetic particles did not capture the normal prion
protein conformer PrPC from uninfected mouse brain tissue
(Fig. 4A), suggesting specificity for the disease-associated conformer, PrPSc. Furthermore, silver stain analysis of total protein indicated that magnetic particles bound minimal protein
from both uninfected and scrapie-infected brain (Fig. 4B).
Other metals, minerals, and resins have been found to interact
with normal and disease-associated prion protein (2, 12, 16,
25). Our findings indicate that superparamagnetic iron oxide
particles capture PrPSc selectively and efficiently.
Detection of prions by PMCA may be made more efficient,
rapid, and sensitive if samples are concentrated for PrPSc prior

FIG. 4. Binding specificity of MagnaBind beads. Binding of PrPSc
and PrPC molecules to MagnaBind-protein A beads. RML scrapieinfected or uninfected mouse brain homogenates were incubated with
MagnaBind-protein A beads for 2 h. (A) Input and bound fractions
were analyzed for PrP molecules by anti-PrP (6D11) immunoblot. The
scrapie brain bound fraction was also analyzed for PrPSc by proteinase
K digestion (⫹PK). (B) Input and bound fractions were analyzed for
total protein by silver staining. All samples were analyzed on the same
gel, with white lines indicating excised intervening lanes.
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FIG. 5. Protein misfolding cyclic amplification (PMCA) reactions
seeded with MagnaBind-bound PrPSc. (A and B) RML-infected mouse
(A) or Sc237-infected hamster (B) brain homogenates before (input)
or after binding by MagnaBind-protein A beads (Mag) or by Dynalprotein A beads (Dyn) were used to seed PMCA reactions. Normal
mouse (A) or hamster (B) brain homogenates were used as substrate.
Prior to PMCA, one set of beads was washed with sarkosyl detergent
(B). Each reaction mixture was analyzed before (⫺) or after (⫹)
PMCA. PrPSc molecules were detected by proteinase K digestion and
anti-PrP (6D11) immunoblot. Control samples were not digested with
proteinase K (⫺PK), to show the amount of PrPC substrate in each
PMCA reaction.

to amplification. This depends on the concentration procedure
leaving PrPSc with the autocatalytic ability to seed the conversion of PrPC. To determine whether magnetic particle-captured PrPSc retained seeding ability, we used bound PrPSc to
seed PMCA reaction mixtures containing normal brain homogenate substrate. RML prion-infected mouse PrPSc successfully seeded the conversion of PrPC to PrPSc, causing amplification of PrPSc (Fig. 5A). We found that captured hamster
Sc237 PrPSc also seeded PMCA, even after the bound PrPSc
was washed stringently with the ionic detergent sarkosyl (Fig.
5B). Thus, magnetically concentrated PrPSc is competent for
amplification by PMCA.
Magnetic capture of PrPSc could be useful to remove
prions from potentially contaminated biological solutions.
We treated a prion-contaminated solution with magnetic
nanoparticles and detected no PrPSc in the supernatant (Fig.
6A). Both MagnaBind beads and magnetite nanoparticles
captured all input PrPSc, leaving none in the remaining fluid.
To test for small amounts of residual PrPSc not detected by
immunoblot, we used nanoparticle-treated supernatants to
seed PMCA reaction mixtures with normal brain homogenate as substrate (Fig. 6B). Input PrPSc was amplified upon
performing PMCA (Fig. 6B, lane 3); in contrast, supernatants treated with MagnaBind and ⬃10-nm nanoparticles
showed no detectable PrPSc, even after amplification by
PMCA (Fig. 6B, lanes 5 and 7). This suggests that nanoparticle treatments are highly effective in removing PrPSc from
contaminated samples.
DISCUSSION
Various materials have been reported to bind prion protein.
Prion infectivity adheres to stainless steel (29), promoted by
nickel and molybdenum, which in isolation also bind to PrPC
and PrPSc (16). Stainless steel has been proposed for prion

2816

J. VIROL.

MILLER AND SUPATTAPONE

FIG. 6. Clearance of PrPSc from solution by magnetic beads or
nanoparticles. RML scrapie-infected mouse brain homogenate was
incubated with MagnaBind-protein A beads (m) or 10-nm magnetite
nanoparticles (n). Particles were then washed twice and resuspended
in buffer. (A) Equal proportions of input, supernatant, each wash, and
bound fractions were analyzed for PrPSc. (B) Binding input, MagnaBind-treated supernatant (Mag sup), nanoparticle-treated supernatant (Nano sup), and buffer alone (no seed) were analyzed for autocatalytic PrPSc by diluting in uninfected mouse brain homogenate and
performing PMCA (⫹). Aliquots of each sample were not subjected to
PMCA (⫺). A control brain homogenate sample was not digested with
proteinase K (⫺PK), to show the amount of PrPC substrate in each
PMCA reaction. All other samples shown in panels A and B were
analyzed for PrPSc by proteinase K digestion. Prion protein was detected by anti-PrP (6D11) immunoblot.

concentration, for use in a coupled concentration-cell culture
detection scheme (9). Prions also adsorb to various minerals
found in soil (14, 20, 27). Phosphotungstic acid has been used
to precipitate PrPSc in the laboratory (26) and may also be used
to concentrate prions for PMCA detection (10). Superparamagnetic nanoparticles present a novel method for binding
and concentrating PrPSc, making use of specific and efficient
capture.
Capture of prions by magnetic nanoparticles holds great
potential to improve current methods of prion detection.
Though the PMCA technique is very sensitive, particularly
when serial amplifications are performed, each round requires
24 to 72 h (7). Nanoparticle-bound PrPSc is competent to seed
PMCA reactions, facilitating the coupling of magnetic nanoparticle concentration with PMCA detection. Another technique, immunoprecipitation, may also be able to concentrate
prions (18, 22), but antibodies directed against PrP may inhibit
prion propagation (19), precluding such a detection scheme.
Coupling of magnetic concentration with PMCA would improve current methods to detect low concentrations of prions,
valuable in safeguarding biological materials for consumption
and in medicine.
Prions may be transmitted to humans by transfusion of infected blood (23). Magnetic nanoparticle capture presents an
opportunity to decontaminate biological products derived
from potentially contaminated sources. Other methods, such
as sodium hydroxide, sodium hypochlorite, and phosphotungstic acid treatments, destroy or remove prions (11, 26) but also
damage the material of interest. In contrast, magnetic nanoparticles capture PrPSc with specificity. Innovative methods,
such as filtration, have been proposed to remove prions from
blood (13). Magnetic capture could potentially reduce the

prion load in contaminated samples while at the same time
facilitating detection. Following treatment with magnetic
nanoparticles, we detected no remaining PrPSc, even after amplification, indicating that nanoparticle capture is effective for
prion removal. The safety of treating biologically derived pharmaceutical products with iron oxide nanoparticles is further
supported by their nontoxicity, demonstrated in clinical studies. The small size of nanoparticles enables passage through
capillary beds, and iron oxide nanoparticles have been approved by the American Food and Drug Administration for
use as a magnetic resonance imaging contrast agent (8). Thus,
superparamagnetic nanoparticles may be used to simultaneously detect and decontaminate prion-contaminated materials.
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